The DOI matches its Crossref record; 412 of the 418 references it cites were found in a registry or an index.
The Amyloid-β Pathway in Alzheimer’s Disease
Open accessAbstract
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer’s disease (AD) pathophysiology. While the detailed molecular mechanisms of the pathway and the spatial-temporal dynamics leading to synaptic failure, neurodegeneration, and clinical onset are still under intense investigation, the established biochemical alterations of the Aβ cycle remain the core biological hallmark of AD and are promising targets for the development of disease-modifying therapies. Here, we systematically review and update the vast state-of-the-art literature of Aβ science with evidence from basic research studies to human genetic and multi-modal biomarker investigations, which supports a crucial role of Aβ pathway dyshomeostasis in AD pathophysiological dynamics. We discuss the evidence highlighting a differentiated interaction of distinct Aβ species with other AD-related biological mechanisms, such as tau-mediated, neuroimmune and inflammatory changes, as well as a neurochemical imbalance. Through the lens of the latest development of multimodal in vivo biomarkers of AD, this cross-disciplinary review examines the compelling hypothesis- and data-driven rationale for Aβ-targeting therapeutic strategies in development for the early treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Traditional neuropathological phases of amyloid-β deposition in Alzheimer’s disease dementia. Red areas in Phase 1 depicts the cortical regions with the initial accumulation of amyloid-β during the early pre-clinical stage. Continued deposition in the same areas are shown in darker colors in the subsequent stages, with the new areas showing amyloid-β in red in each phase. Neocortical regions with the early accumulation of amyloid-β in phase 1 include association cortices. Additional accumulation is seen in allocortical regions and midbrain (phases 2 and 3), with the cerebellum and brain stem having amyloid-β accumulation in late phase clinical stages. The change to darker shading indicates the continuous accumulation of Aβ. Adapted with permission from ref. [13].](https://figures.cochat.ai/paper-figures/e5a44d70ea1143e09c5f08774401df5b/the-amyloid-pathway-in-alzheimers-disease-figure-1.jpg)
![Fig. 2 Hypothetical biomarker evidence-driven model of AD pathophysiology. Hypothetical model of dynamic biomarkers of the AD is expanded to explicate the preclinical phase. Aβ is identified by cerebrospinal fluid Aβ42 assay or PET amyloid imaging. Synaptic dysfunction evidenced by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) or functional magnetic resonance imaging (fMRI), with a dashed yellow line to indicate that synaptic dysfunction may be detectable in carriers of the ε4 allele of the apolipoprotein E gene before detectable Aβ deposition. Neuronal injury is evidenced by cerebrospinal fluid tau or phospho-tau, and brain structure is documented by structural magnetic resonance imaging. Biomarkers change from normal to maximally abnormal (y-axis) as a function of disease stage (x-axis). The temporal trajectory of two key indicators used to stage the disease clinically, cognitive and behavioral measures, and clinical function are also illustrated. Neurofilament light chain (NfL) and neurogranin are newer and potentially more accurate markers of neuronal injury. Figure adapted with permission from ref. [391].](https://figures.cochat.ai/paper-figures/7ed46c7c8b734383b369c38cdc5d4822/the-amyloid-pathway-in-alzheimers-disease-figure-2.jpg)
![Fig. 3 Amyloidogenic vs non-amyloidogenic pathway. Amyloid Precursor Protein (APP) is a single transmembrane protein. For the non-amyloidogenic pathway (left), APP is cleaved by A Disintegrin And Metalloprotease (ADAM) family proteases to yield the membrane-tethered C83 fragment and extracellularly released soluble APP alpha (sAPPα). In the amyloidogenic pathway (right), APP is first cleaved by β-secretase (β-APP-cleaving enzyme-1 or BACE1). CTF-β fragment is subsequently cleaved by γ-secretase composed of Presenilin 1 or 2, Nicastrin, PEN2 and APH-1. This proteolytic processing releases amyloid-β into the extracellular space. APP intracellular domain (AICD) from the initial β-secretase cleavage is released into intracellular space. Adapted with permission from ref. [392].](https://figures.cochat.ai/paper-figures/3740698a98f94719afb3e59ce7300d58/the-amyloid-pathway-in-alzheimers-disease-figure-3.jpg)
![Fig. 4 Amyloid-β aggregation species and evidence of reversible states: the amyloid-β cycle. Aggregation species of Aβ can exist as monomers, dimers, oligomers, protofibril, fibril and amyloid plaques. These species exist in steady state where one form can convert to another in a bidirectional manner. The species are characterized by aggregate size, conformation state and solubility, with fibril and amyloid plaque being insoluble. Adapted with permission from ref. [108].](https://figures.cochat.ai/paper-figures/8538bb3315fc441bbf40d52f125a53d6/the-amyloid-pathway-in-alzheimers-disease-figure-4.jpg)
![Fig. 5 The evidence-driven experimental model of Aβ-tau synergy. Accumulation of neurofibrillary tangles made up of tau (red) and amyloid plaques composed of amyloid-β (blue) coincides in the neocortical areas in the brain of Alzheimer’s disease subjects supporting amyloid-β dependent tau propagation across neocortical regions. Inter-neuronal spreading of tau (bottom) is enhanced in AD brains with both plaques and tangle build-up. Adapted with permission from ref. [221].](https://figures.cochat.ai/paper-figures/fceb1804d6ff427492bb8c0f5ea813ec/the-amyloid-pathway-in-alzheimers-disease-figure-5.jpg)
![Fig. 6 Techniques of in vivo Alzheimer’s disease amyloid-β pathway staging, along the clinical continuum, based on molecular imaging and innovative algorithms. Neocortical distribution of [18F]-florbetapir is shown in a composite representation according to Aβ stages. Early composite (positive in stage 1 in green; left), intermediate composite (positive in stage 2 in blue; middle) and late composite (positive in stage 3 in red; right) can allow global and regional assessment of amyloid plaque deposition. Adapted with permission from: ref. [393].](https://figures.cochat.ai/paper-figures/258ac97d751b433293cf5d46f21104f9/the-amyloid-pathway-in-alzheimers-disease-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Biomarkers play a crucial role in patient selection, biological effect detection, dose optimization, and monitoring response progress, with recent approvals of Aβ monoclonal antibodies benefiting from new and accurate biomarkers.83,423”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Aβ originates from the processing of the amyloid precursor protein (APP) through sequential cleavage by β-secretase and γ-secretase, resulting in various lengths of Aβ fragments, with Aβ40 and Aβ42 being predominant.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The hydrophobic C-terminus of Aβ42 facilitates its aggregation and the formation of senile plaques.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in presenilin-1 (PS1) can promote Aβ accumulation through increased production and impaired autophagy functions.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As AD progresses to its late stages, the effectiveness of nanoparticle-based therapies often diminishes due to the increased disruption of the BBB [148].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [149]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Self-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Self-citation
Research works printed but not linked: 1
- Yamashita K, Hasegawa T, Iino T, Miura M, Watanabe T, Watanabe S, et al. P075-prediction of amyloid pathology by the plasma Aβ(1-42)/Aβ(1-40) ratio measured with fully automated immunoassay system (HISCL™ SERIES). J Prev Alz Dis. 2019;6:S89.
Cited by
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“83,423 The disparity in drug performance between preclinical and human trials has driven the evolution of animal models.”
BackgroundAmyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5319 · Cited by 884
Self-citationClinical applications of stem cell-derived exosomes
Tan, F., Li, X., Wang, Z., Li, J., Shahzad, K., & Zheng, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01704-0 · Cited by 708
Metadata
- Authors
- Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., Masters, C. L., Cho, M., Lannfelt, L., Cummings, J. L., & Vergallo, A.
- Affiliations
- Eisai (United States) (US)
- UK Dementia Research Institute (GB)
- Sahlgrenska University Hospital (SE)
- National University of Singapore (SG)
- The University of Texas at San Antonio (US)
- Hanyang University Seoul Hospital (KR)
- The University of Melbourne (AU)
- University of Southern California (US)
- University of Cambridge (GB)
- The University of Tokyo (JP)
- Uppsala University (SE)
- University of Nevada, Las Vegas (US)
- Corresponding author
- Hampel, Harald
- Vergallo, Andrea
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2021-08-30
- Volume
- 26
- Issue
- 10
- Pages
- 5481-5503
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8758495
- OpenAlex
- W3198052269
- Cited by
- 1,952
- References
- 418
- Citations by year
- 2026: 451 · 2025: 608 · 2024: 468 · 2023: 297 · 2022: 113 · 2021: 15
- FWCI
- 30.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- National University of Singapore (submittedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Molecular Psychiatry
- Apollo
- Funders
- Alzheimer’s Drug Discovery Foundation (RDAPB-201809-2016615)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Alzheimer's disease, tau protein, neuroinflammation, neurodegeneration, synaptic failure, multimodal biomarkers, in vivo biomarkers, disease-modifying therapy, early treatment
- MeSH terms
- Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Amyloid-β Pathway in Alzheimer’s Disease. https://app.cochat.ai/papers/10.1038/s41380-021-01249-0
- The paper
- Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., Masters, C. L., Cho, M., Lannfelt, L., Cummings, J. L., & Vergallo, A. (2021). The Amyloid-β Pathway in Alzheimer’s Disease. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01249-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.